More GMP Inspections by EMA due to Increasing Quality Issues
Recommendation
Wednesday, 21 May 2025 10.00 - 16.00 h
How to use and prepare an MA with a CEP 2.0
Register now for ECA's GMP Newsletter
In its annual report 2011, the European Medicines Agency (EMA) reported about the number of inspections performed in that year. According to the report, the number of GMP inspection requests exceeded the forecast (375 vs. 245). The EMA explained that the number of API inspections and many so-called "for cause" inspections are the reasons for the increase. Another reason for that increase is the large number of complex cases due to significant GMP or general quality issues.
It is remarkable that the quality defects reported have risen by 38% compared to the year 2010. The agency has started a project to identify the reasons for such quality defects. In parallel, the EMA has enhanced collaboration on sharing information about inspections with other agencies such as the US FDA. It is intended to involve further partners in this process. Already today, the US FDA has access to EudraGMP.
Source: EMA Annual Report 2011
Related GMP News
14.05.2025How does FDA train and guide its Inspectors?
30.04.2025QP Declaration: New Q&As published
19.03.2025Root Cause Analysis: Again, problems discovered in GMP-Inspections
19.03.2025ICMRA publishes Hybrid Inspection Pilot Summary Report
19.03.2025From Burkholderia to Ethylene Glycol - a List of Deficiencies at a Manufacturer of OTC Products
19.03.2025Warning Letter - Deficiencies in the Control of Raw and Starting Materials